cis-2,3-dimethylpiperazine | 57193-34-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: cis-2,3-dimethylpiperazine
• 英文别名: 2,3-dimethyl-piperazine；cis-2,3-dimethyl-piperazine；cis-2,3-Dimethyl-piperazin；(cis)-2,3-dimethylpiperazine；cis-2,3-Dimethyl-piperazin；(2R,3S)-2,3-dimethylpiperazine
• CAS: 57193-34-7
• 化学式: C₆H₁₄N₂
• 分子量: 114.191
• InChiKey: COWPTMLRSANSMQ-OLQVQODUSA-N

物化性质

• 熔点：
  49.5-50.5 °C
• 沸点：
  167-168 °C
• 密度：
  0.824±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cis-2,3-dimethylpiperazine 在 氢溴酸 作用下， 以 乙醇 、 异戊醇 、 水 为溶剂， 反应 75.0h， 生成 [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)-cis-2,3-dimethylpiperazin-1-yl]furan-2-ylmethanone
  参考文献：
  名称：

  Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on .alpha.-blocking activity

  摘要：

  Several prazosin-related compounds have been synthesized and evaluated for their blocking activity toward a-adrenoreceptors. The structural modification performed on the prazosin structure included the replacement of the piperazine ring with 2,3-dialkylpiperazine or 1,2-cyclohexanediamine moieties to characterize a lipophilic binding pocket in the alpha1-adrenoreceptor surface. Cyclohexanediamine derivatives 3-6 were almost devoid of potency and selectivity, whereas dialkylpiperazine compounds 7-14 showed high affinity and selectivity toward alpha1-adrenoreceptors. The cis derivative 13 (cyclazosin) was the most potent and selective with an alpha1/alpha2 selectivity ratio value of 7800. The particular trend of antagonist activity within cis/trans stereoisomeric compounds not only supports the presence of a lipophilic binding area on alpha1-adrenoreceptor surface but also suggests that the lipophilic pocket is endowed with a well-defined size and spatial orientation. The most active compound of the series, 13, was tested also in vivo for antihypertensive activity on spontaneously hypertensive rats. It showed an interesting long-lasting hypotensive effect, very similar to that of doxazosin, which was statistically significant 12 h after oral administration.

  DOI：

  10.1021/jm00058a005
• 作为产物：
  描述：

  5,6-二甲基-2,3-二氢吡嗪 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 cis-2,3-dimethylpiperazine
  参考文献：
  名称：

  Ishiguro; Matsumura, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1958, vol. 78, p. 229

  摘要：

  DOI：

文献信息

• MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis

  公开号：EP3875452A1

  公开（公告）日：2021-09-08

  Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

  提供的是式(I)的化合物，或其药学上可接受的盐或溶剂： 还提供了包含式(I)化合物的组合物。这些化合物和组合物还可用作药物，例如用于治疗由单酰基甘油脂酶（MAGL）调节的疾病的药物。还提供了利用这些化合物和组合物来抑制单酰基甘油脂酶（MAGL）的用途。
• Piperazine urea derivatives for the treatment of endometriosis
  申请人：Kaufmann Ulrike

  公开号：US20080119471A1

  公开（公告）日：2008-05-22

  Use of a compound of the following formula (Ia): for the production of a medicament for the treatment of endometriosis in human wherein the treatment comprises administering to a human female in need of such treatment a therapeutically effective amount of said compound.

  使用以下化学式（Ia）的化合物制备治疗人类子宫内膜异位症的药物，其中治疗包括向需要此类治疗的女性人体内给予治疗有效量的该化合物。
• PEPTIDE DEFORMYLASE INHIBITORS
  申请人：Qin Donghui

  公开号：US20090306066A1

  公开（公告）日：2009-12-10

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟基甲酰胺衍生物，包含它们的组合物，这些化合物在抑制细菌肽变形酶（PDF）活性和治疗细菌感染方面的使用。具体而言，本发明涉及式（I）的化合物：其中R1，R2和R3在此定义，并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• Peptide deformylase inhibitors
  申请人：GlaxoSmithKline LLC

  公开号：US07893056B2

  公开（公告）日：2011-02-22

  The present invention is directed to certain 2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide derivatives, compositions containing them, the use of such compounds in the inhibition of bacterial peptide deformylase (PDF) activity, and in the treatment of bacterial infections. Specifically, the invention is directed to compounds of formula (I): wherein R1, R2 and R3 are defined herein and to pharmaceutically acceptable salts thereof. The compounds of this invention are bacterial peptide deformylase inhibitors and can be useful in the treatment of bacterial infections.

  本发明涉及某些2-(烷基)-3-[2-(5-氟-4-嘧啶基)肼基]-3-氧代丙基}羟基甲酰胺衍生物，含有它们的组合物，以及在抑制细菌肽变形酶（PDF）活性和治疗细菌感染方面使用这种化合物。具体而言，本发明涉及式（I）的化合物：其中R1、R2和R3在此定义，并且其药学上可接受的盐。本发明的化合物是细菌肽变形酶抑制剂，可用于治疗细菌感染。
• Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases
  申请人：Alcaraz Lilian

  公开号：US20090149448A1

  公开（公告）日：2009-06-11

  The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

  本发明涉及用于治疗呼吸系统疾病的取代苯氧乙酸类化合物作为有用的药物化合物，包含这些化合物的药物组合物以及它们的制备方法。